Torsdag 26 Februari | 18:13:32 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-16 08:30 Bokslutskommuniké 2026
2026-11-03 08:30 Kvartalsrapport 2026-Q3
2026-09-01 08:30 Kvartalsrapport 2026-Q2
2026-05-29 N/A X-dag ordinarie utdelning IZAFE B 0.00 SEK
2026-05-28 N/A Årsstämma
2026-04-28 08:30 Kvartalsrapport 2026-Q1
2026-03-12 N/A Extra Bolagsstämma 2026
2026-02-16 - Bokslutskommuniké 2025
2025-11-03 - Kvartalsrapport 2025-Q3
2025-08-29 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 - Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder bland annat en läkemedelsrobot, SaaS-lösningar och en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare globalt. iZafe Group har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-02-10 09:00:00

2026 has kicked off with continued high pace and several important developments in both the Swedish and international markets. With many parallel initiatives and rollouts underway, we are strengthening our presence, deepening partnerships, and continuing to build for broader deployment of Dosell, with an even greater focus on scalability and flexibility.

We enter the year with a strong pipeline, an increasing number of inbound requests, and the launch of our new remote care system and display solution – which has been very well received.

Sweden – Growing demand, more procurements, and continued expansion
In Sweden, both interest and market maturity continue to grow. We are now seeing several parallel procurements in addition to the national ADDA tender, a clear indication that medication dispensers have become an integrated part of future healthcare. Several municipalities are also referring to the joint digitalization initiative Handslaget from SKR, which promotes broad implementation of proven welfare technologies – a movement in which Dosell is perfectly aligned.

We continue to maintain strong dialogue with both new and existing municipalities. While lead times are often long due to necessary processes, risk assessments, and anchoring, we are well positioned in many of these. In January, several new quotes and agreement proposals were sent out, and one of our existing customers has already placed a new order for 40 units, along with 15 of our newly launched displays for greater flexibility.

We also conducted five additional digital demonstrations in January and continue to receive new inquiries on an ongoing basis.

The tender submission for Sweden’s first national framework agreement for medication dispensers via ADDA was completed on time by January 5. We also participated in a bid presentation and expect feedback in February. Several municipalities have already signaled their intention to procure Dosell as soon as the agreement is in place.

At the MVTe fair in Stockholm, we launched our remote care platform together with our new modular display. This unique solution makes it possible to use Dosell even for patients who previously could not benefit from a medication dispenser – for example, due to cognitive impairment or a need for more visual guidance.

The response has been very positive. Several municipalities have already requested quotes for the full solution, and we see this as an important complement that can further broaden the target group and increase the value per unit.

Norway – From contract to implementation
Our partnership with Vakt og Alarm has now entered the next phase. The procurement we won with six municipalities began as planned on February 1, and the focus is now on training and implementation. We estimate the initial rollout to include around 100 units and look forward to tracking its progress together with our partner.

The Netherlands – Growth and customer satisfaction
In the Netherlands, our development continues steadily. In January, we signed scale-up agreements with several existing customers and conducted joint evaluations of the implementations. All evaluations confirm high satisfaction, which is also reflected in our latest customer survey: 82.5% of users report being satisfied or very satisfied and would recommend Dosell to others. Several concrete improvement suggestions have been received and are now being implemented.

We have also been contacted by several new potential clients and are engaged in active discussions for pilots and future rollouts. The structural tailwind in the Netherlands is clear – medication dispensers are on their way to becoming the norm in home care, and demand is growing rapidly.

We consider the Netherlands one of our most important markets in Europe. The country has approximately 600,000 patients who receive their medications in dose rolls, compared to around 300,000 in Sweden, which represents a target group twice the size. Additionally, the time from decision to actual implementation is often much shorter than in other countries, offering strong potential for faster growth.

In 2026, we are investing aggressively in the Netherlands by strengthening our local presence. The recruitment of a dedicated Country Manager is in its final stages, with the goal of building a strong local team and scaling the business in pace with sales.

Dosell has also now been approved for inclusion on Digizo.nu – the Dutch national program focused on the broad implementation of proven digital and hybrid care solutions. The program helps healthcare organizations identify effective, validated technologies that deliver real value for patients, users, and professionals. Being listed on Digizo.nu serves as a quality mark, streamlining adoption among new clients and increasing our visibility with both public and private care providers throughout the country.

Iceland – Early-stage groundwork
Preparatory work is underway for a potential market entry in Iceland, where our local partner is engaged in discussions with key stakeholders in both the pharmacy and municipal sectors. There is growing interest in Dosell, and the Icelandic market is characterized by clear national structures, which creates good conditions for coordinated implementation over time.

WHX in Dubai
We are currently participating in the World Health Expo (WHX) in Dubai – the world’s largest healthcare exhibition. The aim of our participation is to meet potential partners and distributors, network with international stakeholders, and identify new opportunities for further expansion.

Looking Ahead – An exciting 2026 has only just begun
We are starting the year with strong momentum and clear visibility. With new markets, stronger solutions, more implementations, and strategic collaborations in place, our focus now is to turn these opportunities into concrete growth. In February, we are prioritizing:

  • Securing additional agreements
  • Awaiting ADDA allocation decisions
  • Starting several planned implementations in February and March
  • Continued follow-ups in Norway, Spain, Iceland, and Finland

Thank you for following our journey!